166 related articles for article (PubMed ID: 17877161)
1. [Effects of the osteoclast in pathogenesis of multiple myeloma].
Zhang JH; Fu JX; Zhang XH; Sun Y
Zhonghua Xue Ye Xue Za Zhi; 2007 May; 28(5):323-6. PubMed ID: 17877161
[TBL] [Abstract][Full Text] [Related]
2. Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin.
Shiotani A; Takami M; Itoh K; Shibasaki Y; Sasaki T
Anat Rec; 2002 Oct; 268(2):137-46. PubMed ID: 12221720
[TBL] [Abstract][Full Text] [Related]
3. Dysregulation of the receptor activator of NF-kappaB ligand and osteoprotegerin production influence the apoptosis of multiple myeloma patients' bone marrow stromal cells co-cultured with myeloma cells.
Zdzisińska B; Bojarska-Junak A; Walter-Croneck A; Kandefer-Szerszeń M
Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):153-63. PubMed ID: 20157786
[TBL] [Abstract][Full Text] [Related]
4. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
5. Effects of RANKL, osteoprotegerin, calcium and phosphorus on survival and activation of Muscovy duck osteoclasts in vitro.
Gu JH; Liu JD; Shen Y; Liu ZP
Vet J; 2009 Sep; 181(3):321-5. PubMed ID: 18682334
[TBL] [Abstract][Full Text] [Related]
6. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
Giuliani N; Colla S; Morandi F; Rizzoli V
Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
[TBL] [Abstract][Full Text] [Related]
7. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
Schubert A; Schulz H; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow adipocytes support dexamethasone-induced osteoclast differentiation.
Hozumi A; Osaki M; Goto H; Sakamoto K; Inokuchi S; Shindo H
Biochem Biophys Res Commun; 2009 May; 382(4):780-4. PubMed ID: 19324007
[TBL] [Abstract][Full Text] [Related]
9. Osteoprotegerin and osteoprotegerin ligand expression during human marrow stromal cell differentiation and their effect on osteoclast formation.
Yang L; Hai Y; Zhou JL
Chin Med J (Engl); 2011 Jul; 124(13):2033-7. PubMed ID: 22088466
[TBL] [Abstract][Full Text] [Related]
10. 17beta-Estradiol overcomes human myeloma RPMI8226 cell suppression of growth, ALP activity, and mineralization in rat osteoblasts and improves RANKL/OPG balance in vitro.
Li Q; Yu K; Tian X; Kong F; You Y; Chen Z; Zou P
Leuk Res; 2009 Sep; 33(9):1266-71. PubMed ID: 19167063
[TBL] [Abstract][Full Text] [Related]
11. Alteration of bone cell function by RANKL and OPG in different in vitro models.
Lin JM; Callon KE; Lin CQ; Bava U; Zheng MH; Reid IR; Cornish J
Eur J Clin Invest; 2007 May; 37(5):407-15. PubMed ID: 17461987
[TBL] [Abstract][Full Text] [Related]
12. Osteoclast culture and resorption assays.
Bradley EW; Oursler MJ
Methods Mol Biol; 2008; 455():19-35. PubMed ID: 18463808
[TBL] [Abstract][Full Text] [Related]
13. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
14. Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro.
Tucci M; Ciavarella S; Strippoli S; Brunetti O; Dammacco F; Silvestris F
Exp Hematol; 2011 Jul; 39(7):773-83.e1. PubMed ID: 21569821
[TBL] [Abstract][Full Text] [Related]
15. Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels.
Kondo T; Kitazawa R; Yamaguchi A; Kitazawa S
J Cell Biochem; 2008 Jan; 103(1):335-45. PubMed ID: 17516544
[TBL] [Abstract][Full Text] [Related]
16. Soluble glucocorticoid-induced tumor necrosis factor receptor stimulates osteoclastogenesis by down-regulation of osteoprotegerin in bone marrow stromal cells.
Shin HH; Kim SJ; Kang SY; Lee DS; Choi HS
Bone; 2006 Oct; 39(4):716-23. PubMed ID: 16750437
[TBL] [Abstract][Full Text] [Related]
17. Long chain polyunsaturated fatty acids alter membrane-bound RANK-L expression and osteoprotegerin secretion by MC3T3-E1 osteoblast-like cells.
Poulsen RC; Wolber FM; Moughan PJ; Kruger MC
Prostaglandins Other Lipid Mediat; 2008 Feb; 85(1-2):42-8. PubMed ID: 18077200
[TBL] [Abstract][Full Text] [Related]
18. [The role of RANK/RANKL and OPG in multiple myeloma].
Zdzisińska B; Kandefer-Szerszeń M
Postepy Hig Med Dosw (Online); 2006; 60():471-82. PubMed ID: 17013366
[TBL] [Abstract][Full Text] [Related]
19. Direct effects of osteoprotegerin on human bone cell metabolism.
Grundt A; Grafe IA; Liegibel U; Sommer U; Nawroth P; Kasperk C
Biochem Biophys Res Commun; 2009 Nov; 389(3):550-5. PubMed ID: 19748486
[TBL] [Abstract][Full Text] [Related]
20. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
Nguyen AN; Stebbins EG; Henson M; O'Young G; Choi SJ; Quon D; Damm D; Reddy M; Ma JY; Haghnazari E; Kapoun AM; Medicherla S; Protter A; Schreiner GF; Kurihara N; Anderson J; Roodman GD; Navas TA; Higgins LS
Exp Cell Res; 2006 Jun; 312(10):1909-23. PubMed ID: 16600214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
